Abstract
Enone prodrugs of dopaminergic catecholamines represent a new type of prodrug in the research area of dopamine agonists. Here, we demonstrate the first benzo[g]quinoline-derived enone that induces potent dopamine agonist effects similar to aminotetralin-derived enones. Significant effects of (-)-4 were observed in microdialysis studies after administration of 1 nmol kg(-1) sc and 3 nmol kg(-1) po. With a potency comparable to that of the most potent apomorphines, (-)-4 could potentially compete with L-DOPA and apomorphine in the treatment of Parkinson's disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
2-Naphthylamine / analogs & derivatives*
-
2-Naphthylamine / chemistry
-
Administration, Oral
-
Animals
-
Corpus Striatum / metabolism
-
Crystallography, X-Ray
-
Dopamine Agonists / chemical synthesis*
-
Dopamine Agonists / chemistry
-
Dopamine Agonists / pharmacology
-
In Vitro Techniques
-
Microdialysis
-
Prodrugs / chemical synthesis*
-
Prodrugs / chemistry
-
Prodrugs / pharmacology
-
Quinolines / chemical synthesis*
-
Quinolines / chemistry
-
Quinolines / pharmacology
-
Quinolones / chemical synthesis*
-
Quinolones / chemistry
-
Quinolones / pharmacology
-
Radioligand Assay
-
Rats
-
Receptors, Dopamine D1 / metabolism
-
Receptors, Dopamine D2 / metabolism
-
Receptors, Dopamine D3 / metabolism
-
Stereoisomerism
-
Structure-Activity Relationship
Substances
-
1-propyl-2,3,4,4a,5,7,8,9,10,10a-decahydro-1H-benzo(g)quinolin-6-one
-
Dopamine Agonists
-
PD 148903
-
Prodrugs
-
Quinolines
-
Quinolones
-
Receptors, Dopamine D1
-
Receptors, Dopamine D2
-
Receptors, Dopamine D3
-
2-Naphthylamine